Glenmark Pharmaceuticals announced the approval of its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The Board also approved the reconstituted Risk Management Committee and amendments to various company policies. A record date of August 31, 2026, has been set for determining shareholder entitlement to dividends for the financial year ended March 31, 2026. The 48th Annual General Meeting is scheduled for September 11, 2026.
Glenmark Pharmaceuticals Announces Q1 FY27 Financials
On July 31, 2026, Glenmark Pharmaceuticals Limited held a Board meeting where the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026 were approved. The company also submitted the Limited Review Report on these financial results.
Key Corporate Actions
The Board of Directors also approved several key corporate actions:
- Amendments to the following policies: Policy on Related Party Transactions and its Materiality; Policy on Determination of Materiality for Disclosures; Insider Trading Policy; Dividend Distribution Policy; and Nomination and Remuneration Policy.
- Reconstitution of the Risk Management Committee, effective August 01, 2026. Ms. Patricia Andrews has been appointed as Chairperson, with Mr. Glenn Saldanha, Mr. Anurag Mantri, and Mr. Dipankar Bhattacharjee as Members.
Annual General Meeting and Dividend
The 48th Annual General Meeting (AGM) is scheduled to be held on Friday, September 11, 2026, at 2:00 P.M. via video-conferencing. The proceedings will be deemed to be conducted at the company’s Corporate Office. The record date for determining dividend entitlement for the financial year ended March 31, 2026, has been fixed as Monday, August 31, 2026.
Financial Highlights (Standalone)
For the quarter ended June 30, 2026, Glenmark Pharmaceuticals reported:
- Total income of ₹25,504.04 million.
- Profit after tax of ₹7,356.37 million.
- Total comprehensive income of ₹7,362.43 million.
Financial Highlights (Consolidated)
For the quarter ended June 30, 2026, on a consolidated basis:
- Total income stood at ₹40,842.47 million.
- Profit after tax was ₹4,828.28 million.
- Total comprehensive income amounted to ₹5,232.76 million.
Notes on Financials
The financial results have been prepared in accordance with Indian Accounting Standards (Ind AS 34) and comply with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The results were reviewed by the Audit Committee and approved by the Board. Statutory auditors have provided an unmodified review conclusion.
Key exceptional items for the standalone results include a cash consideration of ₹2,230 million from the transfer of Nebulizer brands to a wholly-owned subsidiary. For standalone and consolidated results, a provision for an estimated settlement amount of ₹3,232.32 million and ₹2,780.70 million respectively, related to antitrust and consumer protection lawsuits in the U.S., has been recognized as an exceptional item.
Source: BSE
